Novel immunotherapies for breast cancer: Focus on 2023 findings

Lan, Huan-Rong; Chen, Min; Yao, Shi-Ya; Chen, Jun-Xia; Jin, Ke-Tao

doi:10.1016/j.intimp.2024.111549

Cited by 1 publication

(1 citation statement)

References 203 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancer is a complex and heterogeneous disease that poses many challenges for research and treatment. Some of these challenges are to determine cancer subtypes, to understand the aggressiveness of cancer [ 28 ], neoadjuvant treatment response [ 29 ], or why most breast cancer patients do not respond to immunotherapy [ 30 ]. Another area of research is to develop predictive biomarkers for personalized medicine in breast cancer [ 31 , 32 ].…”

Section: Breast Cancer Therapies and Open Research Questionsmentioning

confidence: 99%

The Revolution in Breast Cancer Diagnostics: From Visual Inspection of Histopathology Slides to Using Desktop Tissue Analysers for Automated Nanomechanical Profiling of Tumours

Stolz

2024

Bioengineering

View full text Add to dashboard Cite

We aim to develop new portable desktop tissue analysers (DTAs) to provide fast, low-cost, and precise test results for fast nanomechanical profiling of tumours. This paper will explain the reasoning for choosing indentation-type atomic force microscopy (IT-AFM) to reveal the functional details of cancer. Determining the subtype, cancer stage, and prognosis will be possible, which aids in choosing the best treatment. DTAs are based on fast IT-AFM at the size of a small box that can be made for a low budget compared to other clinical imaging tools. The DTAs can work in remote areas and all parts of the world. There are a number of direct benefits: First, it is no longer needed to wait a week for the pathology report as the test will only take 10 min. Second, it avoids the complicated steps of making histopathology slides and saves costs of labour. Third, computers and robots are more consistent, more reliable, and more economical than human workers which may result in fewer diagnostic errors. Fourth, the IT-AFM analysis is capable of distinguishing between various cancer subtypes. Fifth, the IT-AFM analysis could reveal new insights about why immunotherapy fails. Sixth, IT-AFM may provide new insights into the neoadjuvant treatment response. Seventh, the healthcare system saves money by reducing diagnostic backlogs. Eighth, the results are stored on a central server and can be accessed to develop strategies to prevent cancer. To bring the IT-AFM technology from the bench to the operation theatre, a fast IT-AFM sensor needs to be developed and integrated into the DTAs.

show abstract

Section: Breast Cancer Therapies and Open Research Questionsmentioning

confidence: 99%

The Revolution in Breast Cancer Diagnostics: From Visual Inspection of Histopathology Slides to Using Desktop Tissue Analysers for Automated Nanomechanical Profiling of Tumours

Stolz

2024

Bioengineering

View full text Add to dashboard Cite

show abstract

Novel immunotherapies for breast cancer: Focus on 2023 findings

Cited by 1 publication

References 203 publications

The Revolution in Breast Cancer Diagnostics: From Visual Inspection of Histopathology Slides to Using Desktop Tissue Analysers for Automated Nanomechanical Profiling of Tumours

The Revolution in Breast Cancer Diagnostics: From Visual Inspection of Histopathology Slides to Using Desktop Tissue Analysers for Automated Nanomechanical Profiling of Tumours

Contact Info

Product

Resources

About